Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 18/20 | 0.43 |
| ▸ | PDE4A | P27815 | 11/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | PDE1A | P54750 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7863888 | 0.81 | PDE4B (0.52) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL7855708 | 0.78 | PDE4B (0.50) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL11993028 | 0.76 | PDE4B (0.59) | PDE4BPDE4APDE4CPDE4DMAPT | |
| SCHEMBL18015950 | 0.74 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL7863402 | 0.73 | PDE4B (0.74) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL7855804 | 0.73 | PDE4B (0.45) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL18015961 | 0.73 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL7864419 | 0.73 | PDE4B (0.54) | PDE4BPDE4APDE4CPDE4DMAPT | |
| SCHEMBL7862771 | 0.72 | PDE4B (0.54) | PDE4BPDE4APDE4CPDE4DMAPT | |
| SCHEMBL7861724 | 0.72 | PDE4B (0.49) | PDE4BPDE4APDE4CPDE4DKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039450-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | NFKBIA, LITAF, CD68 | PDE4B 776/4885PDE4A 1019/4885PDE4C 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.